Abstract C36: The prognostic effect of HER3 among gastric cancer patients.
Authors: Soltani Delgosha Mehrdad , Makhdoumi Yasha 
Published: August 2014

Abstract
Introduction: The epidermal growth factor receptors (EGFR) family stimulates a number of signal transduction cascades that regulate diverse cellular processes, such as proliferation, differentiation, survival, migration, and adhesion. These signaling pathways are important in normal cellular homeostasis but aberrant activation of the EGFR members can cause carcinogenesis. The carcinogenic role of HER3 and HER4 has been seen in gastric cancer. In this study, the prognostic effect of HER3 is evaluated in gastric cancer patients.
Materials and Methods: Tumoral and free tumoral borders of gastric tissues were freshly obtained from 40 patients with primary gastric adenocarcinoma who underwent a surgical procedure. The patients who underwent gasterectomy did not get any neoadjuvant therapy. Histopathological features including tumor size, location, and grade of differentiation were defined and surgical stage was determined on the basis of the union international cancer TNM classification. RNA was extracted from normal and cancerous tissue of gastric samples using the RNeasy Mini kit (Qiagen, Hilden, Germany) and then the cDNA was synthesized by using synthesis kit (Fermentas, Lithuania) after that Quantitative Real-time PCR was performed by using SYBR green PCR master Mix (Fermentas, Lithuania) to evaluate the expression of HER3 in species. To determine the prognosis, we followed the patients’ situation for 6 and 12 months after surgery, then the correlation between HER3 (mRNA) and prognosis was determined. Statistical analysis was done by spss ver 19, for assessing the correlation between HER3 and clinicopathological factors used Independant sample T test and Kaplan-Meier curves were generated for overall survival, statistical significance was determined using Log-rank test.
Results: 77.5% of patients were male and 22.5% were female, 52.5% of patients were older than 65 years whereas, 47.5% were less than 65. 35% of patients have HER3 over expression. HER3 expression was significantly associated with factors involved with tumor progression, including depth of tumor T1-T2 (P=0.000); involved lymph nodes (P=0.001); stage (P=0.000); recurrent disease (P=0.000); and CA 19-9 (P=0.000). The significant relationship between mRNA and protein of HER3 was seen.(P=0.000) HER3 over expression was associated with a significantly worse survival.(P=0.000) the protein of HER3 was an independent prognostic factor in the multivariate analysis, (P=0.007) 95% confidence interval was 0.006-0.454.
Conclusion: HER3 is an independent prognostic factor which can cause tumor progression and poorer survival rate of patients, in cellular and molecular study is demonstrated that anti agents which target HER2 can cause compensatory over expression of HER3, so that, the unexpected result would be gained and prognosis would be poor, therefore, we suggest, assessing the expression HER3 in patients and use regime which target the band between HER2 and HER3 to get proper results and improve the prognosis.
Citation Information: Mol Cancer Ther 2013;12(11 Suppl):C36.
Citation Format: Mehrdad Soltani Delgosha, Yasha Makhdoumi. The prognostic effect of HER3 among gastric cancer patients. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2013;12(11 Suppl):Abstract nr C36.